Phaseline

Companies › Rapa Therapeutics

Rapa Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Neurology, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RAPA-501 Autologous T stem cells
Autologous hybrid TREG/Th2 cells
–Phase 2Amyotrophic Lateral SclerosisJul 2027
RAPA-201 Rapamycin Resistant T Cells
Autologous rapamycin-resistant CD4+ and CD8+ T cells (Th1/Tc1 phenotype) with checkpoint-d
–Phase 1Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05144698RAPA-201 Rapamycin Resistant T CellsPhase 1Solid TumorOncologyDec 2026
NCT04220190RAPA-501 Autologous T stem cellsPhase 2Amyotrophic Lateral SclerosisNeurologyJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

MeiraGTx Scancell Allotera Therapeutics Ever Supreme Bio Technology Diakonos Oncology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.